Answers are grounded in this paper and cite their sources.
WHAT IS KNOWN AND OBJECTIVE: Liposomal amphotericin B (L-AmB) is the cornerstone of many serious invasive fungal infections. Despite lower frequencies of commonly reported adverse events in clinical trials compared to conventional formulations, post-marketing complications continue to mount. CASE DESCRIPTION: We present a case of chest pain following the initial dose of L-AmB for cryptococcal meningitis. Electrocardiogram demonstrated no acute electrocardiogram findings. Upon rechallenge, the chest pain worsened was subsequently accompanied by ST-segment elevation. Emergent coronary angiography found no acute findings. WHAT IS NEW AND CONCLUSION: Providers should be aware of cardiac complications with L-AmB, including non-occlusive ST-segment elevation.
No takes yet. Share an insight, caveat, or question.
Kullab et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: